Machines were used to examine the glycemic impact of various meals to determine a glucose forecast.
The studies will assess the safety, efficacy, and user-friendliness among other aspects, of multiple artificial pancreas devices.
Patients with type 1 diabetes who used multiple insulin injections daily experienced reductions in HbA1c with continuous glucose monitoring.
The FDA's expanded indication for the Dexcom G5 Continuous Glucose Monitoring System allows for replacement of fingerstick glucose testing.
The system allows patients and their caregivers to access glucose measurements through their pump or through a mobile app.
The Contour®Next One Blood Glucose Management System will be available in early 2017.
An implantable continuous glucose monitor appears to be a safe and effective alternative to a transcutaneous monitor in diabetes.
FDA approval of the first closed-loop insulin delivery system is exciting for both physicians and patients. What does this mean for the future?
Approval was based on a clinical trial that included 123 people with type 1 diabetes who used the MiniMed 670G hybrid closed-loop system for 3 months, after a 2-week period of no use.
The FDA is coordinating with investigators, manufacturers, clinicians, and others to bring automated insulin delivery devices to market.
The system was feasible, safe, and effective for managing hyperglycemia in this patient population.
Artificial pancreas was linked to 3-fold reduction of time-in-hypoglycemia for 5- to 9-year-olds.
Overnight-only and 24/7 closed-loop control reduced hypoglycemia and increased time in range.
The paper raises questions regarding safety for measuring blood glucose, and when blood glucose meters are used in trials.
Experts are now calling for a more standardized and transparent approach to identifying and reporting adverse events with insulin pump therapy.
The FDA has cleared the t:flex Insulin Pump, which has the largest capacity available in the U.S., for marketing.
The FDA has approved the Animas Vibe insulin pump and continuous glucose monitoring system for patients with diabetes.
Type 1 diabetes patients experienced improved glucose control and less hypoglycemia with use of an artificial pancreas vs. sensor-augmented pump therapy.
Roche announced the launch of Accu-Chek Aviva Expert system, the first blood glucose meter with a built-in insulin calculator.
Patients with type 1 diabetes may improve glucose control while reducing the frequency of hypoglycemic episodes with the arrival of the artificial pancreas.
Endocrinology Advisor Articles
- Semaglutide Improved Beta-Cell Function and Glycemic Control in Type 2 Diabetes
- Blood Glucose Self-Monitoring in Type 2 Diabetes Does Not Benefit Glycemic Control
- Elagolix Relieves Short-Term Menstrual Pain, Dysmenorrhea in Endometriosis
- Improving Glycemic Control in T2D With Text Message Intervention
- The Handoff: Your Week in Endocrinology News - 6/23/17
- Reduced Cardiovascular Events in Type 2 Diabetes Treated With Dapagliflozin
- Prolonged Delayed Eating Linked to Weight Gain, Increased Respiratory Quotient
- Canagliflozin Reduces Cardiovascular Stress In Older Patients With Type 2 Diabetes
- GLP-1 Analog Counteracts Antipsychotic-Induced Glucose Intolerance, Weight Gain
- Diabetic Retinopathy Caused by Sleep Apnea in T2D
- USPSTF Updates Recommendations for Screening Obesity in Children and Adolescents
- Exercise Protocol Improves Outcomes in T2D
- Interspersed Upper Body Activity With Sedentary Time Improves Glucose, Insulin
- AHA Advisory: Replace Saturated Fat to Reduce CVD By 30%
- Type 2 Diabetes Death and CV Events Predicted by Systolic Blood Pressure Variability